Please login to the form below

Not currently logged in
Email:
Password:

Isentress

This page shows the latest Isentress news and features for those working in and with pharma, biotech and healthcare.

MSD claims EU approval for two HIV products

MSD claims EU approval for two HIV products

Isentress is used as an add-on therapy to other HIV drugs and brought in $1.2bn in sales last year, but has started to be squeezed by new products from ... At the time, GlobalData analyst Thomas Moore said that while the two drugs are “unlikely to

Latest news

  • A new option for people with HIV A new option for people with HIV

    Other integrase inhibitors. Raltegravir ( Isentress; Merck) was the first integrase inhibitor to be approved by the US FDA in October 2007. ... tenofovir disoproxil fumarate (Atripla) and raltegravir (Isentress).

  • FDA clears Isentress formulation for infants with HIV FDA clears Isentress formulation for infants with HIV

    A new formulation of Merck &Co's drug Isentress has been cleared in the US to treat infants and children with HIV infection. ... By expanding the potential audience of Isentress, Merck will hope it can keep up in an increasingly competitive market for

  • ViiV's Tivicay for HIV on course for EU approval ViiV's Tivicay for HIV on course for EU approval

    Tivicay is the third entrant in the integrase inhibitor class after Merck &Co's Isentress (raltegravir) - which was first approved in 2007 - and Gilead Sciences' elvitegravir which was approved last year ... As the first entrant, Isentress is enjoying

  • ViiV gets US nod for HIV drug dolutegravir ViiV gets US nod for HIV drug dolutegravir

    a twice-daily treatment with rival integrase inhibitor Isentress (raltegravir) from Merck &Co and found they were equivalent in previously-untreated HIV patients. ... The SAILING study found that Tivicay was more effective than Isentress in suppressing

  • Merck profit slides as generics continue to bite Merck profit slides as generics continue to bite

    HIV drug Isentress (raltegravir) climbed 5 per cent to $410m, holding up fairly well despite increased competition from the likes of Gilead Sciences' elvitegravir, while sales of cholesterol drugs Zetia (ezetimibe)

More from news
Approximately 1 fully matching, plus 21 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Langland

We love what we do and we think it shows.It shows in the work we do, the space we work...

Latest intelligence

PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story
How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
AI healthcare
Three ways AI will change healthcare in the next decade
Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...

Infographics